Project description DEENESFRITPL Safe 3D imaging system for breast tissue Breast cancer is the second leading type of cancer in women worldwide. In 2018, 2 million new cases were recorded and over 620 000 deaths. Mass screening programmes and early diagnosis are based on mammography. However, this produces harmful side effects and false-positive results, requiring additional screenings. A new, more safe and precise method is a necessity. The EU-funded LOUISA 3D project will provide an innovative, non-invasive clinical breast imaging system using optoacoustic technology. This will produce scans at different wavelengths to visualise multiple features of the tissue, without patient discomfort. Project work will enable safe, precise detection and diagnostics of cancer and vascular diseases. Show the project objective Hide the project objective Objective Breast cancer is a global challenge representing the leading cause of death for women worldwide: according to theestimates of WHO, there were over 2 million new cases in 2018, with a projection of more than 3 million individuals by 2040.It is usually diagnosed at an advanced stage while early detection greatly increases the chances for successful treatment.The 2 components of early detection are mass screening and early diagnosis. Currently, most diffuse population-basedscreening programs for breast cancer are based on mammography. Weighing the harms against the benefits of theseprograms has led WHO not to recommend mammography screening in women less than 50 years of age. Mammographyhas been the medical industry’s “gold standard” breast cancer screening tool for nearly four decades. Today a number ofadverse effects, backed up by mounting scientific evidence, are limiting the use of mammography as a mass screeningdevice. LOUISA-3D uses safe light and sound to provide safer and accurate breast cancer screening. The LOUISA-3Dinnovation consists of a novel optoacoustic imaging method that allows one to see under the skin through the tissues withhigh spatial resolution by listening to the sound of light absorbed in the body which can be used for detection and diagnosticsof cancer and vascular diseases. During the phase 1 project, a go-to-market strategy and a supply chain will be established,as well as further development plan will be drafted. Within the overall innovation project Tomowave will finalize itsengineering of LOUISA-3D before scaling up for clinical trials and system industrialization. Fields of science medical and health sciencesclinical medicineangiologyvascular diseasesmedical and health sciencesclinical medicineoncologybreast cancernatural sciencesphysical sciencesopticslaser physicsnatural sciencesphysical sciencesacousticsultrasound Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TOMOWAVE SYSTEMS LTD Net EU contribution € 50 000,00 Address UNIT 6 QUEEN'S YARD WHITE POST LANE E9 5EN LONDON United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region London Inner London — East Tower Hamlets Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00